Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 50,000 shares at $12.31 ($616K) on 2025-02-03, disclosed to the SEC on 2025-02-04.
Scheduled sale ($616k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |
| SPRY | SELL | 2023-09-05 | $771K | — | Filing → |